NEW YORK--(BUSINESS WIRE)--Bioenvision, Inc. (NasdaqGM:BIVN) today announced that data from its pivotal Phase II clinical trial of Evoltra® (clofarabine) will be given in an oral presentation at the 48th Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida, December 8-12, 2006.
